Evidence map›Paper›PMID 31602317›Full record

ArticleConvergent science physical oncology2015

Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.

David W Nauen, Andrew Guajardo, Lisa Haley, Kerry Powell, Peter C Burger, Christopher D Gocke

Abstract read
In one paragraph

Article in Convergent science physical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David W NauenDepartment of Pathology, Johns Hopkins Hospital, Ross 558, 720 Rutland Avenue, Baltimore MD 21205, USA.
Andrew GuajardoDepartment of Pathology, Johns Hopkins Hospital, Ross 558, 720 Rutland Avenue, Baltimore MD 21205, USA.
Lisa HaleyDepartment of Pathology, Johns Hopkins Hospital, Ross 558, 720 Rutland Avenue, Baltimore MD 21205, USA.
Kerry PowellDepartment of Pathology, Johns Hopkins Hospital, Ross 558, 720 Rutland Avenue, Baltimore MD 21205, USA.
Peter C BurgerDepartment of Pathology, Johns Hopkins Hospital, Ross 558, 720 Rutland Avenue, Baltimore MD 21205, USA.
Christopher D GockeDepartment of Pathology, Johns Hopkins Hospital, Ross 558, 720 Rutland Avenue, Baltimore MD 21205, USA.

Funding

Research Education Program in Experimental NeuropathologyR25NS079185 · NINDS · JOHNS HOPKINS UNIVERSITY · PI TRONCOSO, JUAN · 2012 to 2017
$364k
NINDS NIH HHS R25 NS079185
6 · The paper itself

Abstract

To assess karyotypic changes and tumor subpopulations in progression of oligodendroglioma (ODG) we analyzed histologically diagnosed 1p/19q codeleted cases using single nucleotide polymorphism (SNP) microarray data. We separated cases according to grade, which was assigned blind to karyotype information beyond 1p/19q status. The 51 WHO grade II (O2) and 18 WHO grade III (O3) specimens showed frequent chromosomal locations and patterns of change including loss of heterozygosity (LOH), often copy-neutral, on 9p and LOH on 4p and 4q together. Analysis of co-occurrence indicated that most defects were independent but also suggested increased likelihood of defects on 11q, 13q, and 14q in the presence of defects on 18, 4, and 9, respectively. We used the relative degree of change in B-allele frequency as an indicator of an abnormality's extent, and we present simulated data to clarify how information on subpopulations was thus inferred. Among 9p defects, 89.3% involved the whole tumor, whereas only 47.6% of 4q defects did so. We modeled extent through the tumor as due to a karyotypic change's likelihood of occurring and the fitness it confers on its subpopulation, and used group data to estimate these values. To assess progression directly, we evaluated specimens from six patients who underwent multiple resections since 1996. Four of these patients had received no chemotherapy or radiation, permitting assessment of the natural history of the tumor karyotype

Indexed as

1p/19qheterogeneitymicroarrayoligodendrogliomaprogressionsubpopulation

Identifiers

PMID31602317
PMCPMC6786500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.